Sanofi, a France-based multinational pharmaceutical company, is investing EUR80m in equity in BioNTech, which is claimed to be Europe's largest privately-held biopharmaceutical firm focused on the development of individualised therapies for cancer and the prevention of infectious diseases, it was reported yesterday.
According to the contract, BioNTech is eligible to receive USD60m in upfront and near-term milestone payments. The firm is also eligible to receive more than USD300m in development, regulatory and commercial milestones and other payments per product.
The company has the option to co-develop and co-commercialiSe two of the five mRNA therapeutics products with Sanofi in the European Union and the United States.
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Ondine's Steriwave proven effective against deadly Mucor fungus
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025
GC Biopharma's BARYTHRAX receives Korean regulatory approval
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management